Healey & AMG Center Announces Update in ALS Platform Trial with Trehalose
The Healey & AMG Center has announced the latest updates regarding Regimen E of the HEALEY ALS Platform Trial evaluating Trehalose.
Dr. Paganoni is an Associate Professor at Harvard Medical School and works as a physician scientist at the Healey Center for ALS at Massachusetts General Hospital and at Spaulding Rehabilitation Hospital.Her research focuses on clinical trials and therapy development for ALS. She has served as PI of several ALS clinical trials and has been using novel trial designs, novel endpoints and digital technology tools to innovate the way investigational products are tested in ALS. She is the co-PI of the HEALEY ALS Platform Trial, the first platform trial for ALS in the world. She recently reported the positive results of the CENTAUR trial and is the co-Chair of the global PHOENIX trial.She is also working with people with Primary Lateral Sclerosis (PLS), a rare form of Motor Neuron Disease, and Hereditary Spastic Paraplegia (HSP). She co-chairs the PLS Task Force and the PLS registry of the Northeast ALS Consortium (NEALS). She is working with other Harvard researchers on developing new assistive technology devices that can improve function and quality of life for people with ALS and other forms of Motor Neuron Disease. Dr. Paganoni published >100 peer-reviewed papers. She is an editorial board member for Muscle and Nerve and the American Journal of PM&R where she is also Associate Editor for the Section Evidence-Based Physiatry/Cochrane Corner. Her research has been funded by the NIH, foundations, and industry. She received several awards for her work including the NIH Rehabilitation Medicine Scientist Training Program Award (2012), the American Academy of Neurology / ALS Association Three-Year Career Development Award in ALS (2017), the American Association of Neuromuscular & Electrodiagnostic Medicine Scientific Impact Award (2019), the Top 10 Clinical Research Achievement Award (2021), and the Martin Prize for Excellence in Clinical Research Award (2021).Dr. Paganoni holds 3 Board Certifications (Physical Medicine and Rehabilitation, Neuromuscular Medicine, and Electrodiagnostic Medicine). She is a member of the Association of Academic Physiatrists (AAP), American Academy of Neurology (AAN), and American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
Clinical Interests:
Treats:
Languages:
Sean M. Healey and AMG Center for ALS
55 Fruit Street
Wang Ambulatory Care Center
8th Floor
Boston, MA 02114
Phone: 617-724-3914
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Collaboration between Healey Center investigator Sabrina Paganoni, MD, PhD and Amylyx Pharmaceuticals has created promising results for patients.
The Healey & AMG Center has announced the latest updates regarding Regimen E of the HEALEY ALS Platform Trial evaluating Trehalose.
DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR).
The grant is supported by the ACT for ALS (Accelerating Access to Critical Therapies for ALS Act), and this study is the very first EAP made possible by the bill.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Northeast ALS (NEALS) Consortium announced results from Regimen D of the HEALEY ALS Platform Trial evaluating pridopidine versus placebo in adults with amyotrophic lateral sclerosis (ALS).
The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) today announced topline results from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc.
The Healey & AMG Center for ALS at Mass General and Calico Life Sciences LLC recently signed an agreement to work together to test ABBV-CLS-7262 in the HEALEY ALS Platform Trial.